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NAD+-dependent lysine deacetylases (sirtuins, SIRT1-
7) have emerged as potential therapeutic targets for 
treatment of human illnesses such as cancer, metabolic, 
cardiovascular and neurodegenerative diseases. Sirtuins 
possess deacetylase and/or mono-ADP-
ribosyltransferase activity, and this activity is directed 
to histone as well as non-histone targets involved in 
transcription, metabolism, and energy homeostasis 
[1,2]. SIRT1, having in cells a nuclear localization, has 
been widely recognized to play a multifaceted, 
protective role in aging, metabolism, and 
neurodegeneration [3]. In cancer, the role of SIRT1 is 
highly debated. Among SIRT1/2 inhibitors, sirtinol 
induced senescence-like growth arrest in human breast 
cancer MCF-7 cells and lung cancer H1299 cells [4] 
and inhibited cell growth in prostate cancer [5]; 
cambinol induced apoptosis in BCL6-expressing Burkitt 
lymphoma cells [6]; salermide was well tolerated by 
mice at concentrations up to 100 μM and prompted 
tumor-specific apoptosis in a wide range of human 
cancer cell lines [7]; MC2141 displayed high 
antiproliferative activity against Raji, DLD1, and HeLa 
cells [8], and tenovins, identified via a yeast genetic 
screen for p53 activators, decreased tumor growth in 
vivo as single agents at low micromolar concentrations 
[9]. On the other hand, in some contexts SIRT1 seems 
to have a protective role in cancer, in particular in colon 
cancer. SIRT2 is a cytoplasm enzyme mainly known as 
α–tubulin deacetylase, highly involved in cell cycle 
regulation. SIRT2 crucially regulates the functions in 
the mitotic checkpoint elicited by mitotic stress, as well 
as cell death in response to DNA damage-inducing 
stress [10]. In addition, SIRT2 influences adipocyte 
differentiation by deacetylation of FOXO proteins. 
Despite early evidences suggested SIRT1 as the main 
sirtuin target to inhibit for obtaining anticancer 
properties, recently SIRT2 down-regulation has been 
described to lead to apoptosis without cell cycle arrest 
in HeLa cells [11]. SIRT3-5 are mithocondrial 
deacetylases or ADP-ribosylases (SIRT4), and control 
adaptive thermogenesis (SIRT3), aging (SIRT3), insulin 
secretion (SIRT4), and ammonia detoxification (SIRT5) 
[1]. Finally, SIRT6 and SIRT7 are two nuclear and 
nucleolar enzymes,  the first involved  in  the control  of  
 
 
                                        Editorial Comment 
 
 
 
 
 
 
 
 
genomic DNA stability and DNA repair as well as 
glucose homeostasis, the latter exerting antiapoptotic 
properties [1].  
In this month issue of AGING, Schlicker et al. described 
the identification of specific and semi-specific SIRT 
inhibitors through virtual screening performed by 
docking 1990 structurally different compounds into the 
peptide binding pockets of crystal structures of SIRT2, -
3, -5, and -6. To avoid to select compounds blocking the 
NAD+ binding site, that is common to all the sirtuins 
and could highlight non isoform-specific compounds, 
the four SIRTs/NAD+ complexes have been used. For 
each docking run, the 10 top-ranking compounds have 
been selected and tested against SIRT2, -3, -5, and -6. 
Among the 20 compounds found active, 14 were 
selective for SIRT2, and 6 were able to inhibit, in 
addition to SIRT2, one (3 compounds) or two (2 
compounds) or all (1 compound) of the other tested 
sirtuins. Interestingly, some compounds behaved as 
SIRT5 and/or SIRT6 activators. Two selected SIRT2-
specific inhibitors, CSC8 and CSC13, bearing a steroid 
scaffold were selected for further studies. Dose-
response curves gave IC50 values against SIRT2 of 4.8 
(CSC8) and 9.7 (CSC13) µM. Tested against SIRT1, 
the two compounds showed weak inhibition at 100 µM. 
In functional tests in HEK cells, CSC13 increased the 
acetyl-α-tubulin level at 100 µM, thus confirming its 
SIRT2 inhibition at a cellular level. Such compound in 
particular seems to be interesting for further develop-
ment, since carrying a 2-phenylpyrimidine moiety fused 
to the tetracyclic gonane structure, it is not predicted to 
interact with nuclear receptors, and thus it should be 
devoid of steroid receptor-mediated side effects. 
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